Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 2
2003 2
2004 1
2005 2
2008 2
2009 1
2010 3
2011 4
2012 2
2013 2
2014 6
2015 8
2016 22
2017 22
2018 23
2019 17
2020 26
2021 24
2022 28
2023 24
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Results by year

Filters applied: . Clear all
Page 1
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, Di Fiore F, Cripps C, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux JL, Juzyna B, Gourgou S, O'Callaghan CJ, Jouffroy-Zeller C, Rat P, Malka D, Castan F, Bachet JB; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. Conroy T, et al. Among authors: ben abdelghani m. N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMoa1809775. N Engl J Med. 2018. PMID: 30575490 Clinical Trial.
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.
Conroy T, Castan F, Lopez A, Turpin A, Ben Abdelghani M, Wei AC, Mitry E, Biagi JJ, Evesque L, Artru P, Lecomte T, Assenat E, Bauguion L, Ychou M, Bouché O, Monard L, Lambert A, Hammel P; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. Conroy T, et al. Among authors: ben abdelghani m. JAMA Oncol. 2022 Nov 1;8(11):1571-1578. doi: 10.1001/jamaoncol.2022.3829. JAMA Oncol. 2022. PMID: 36048453 Free PMC article. Clinical Trial.
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.
Conroy T, Galais MP, Raoul JL, Bouché O, Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C, François E, Créhange G, Abdelghani MB, Juzyna B, Bedenne L, Adenis A; Fédération Francophone de Cancérologie Digestive and UNICANCER-GI Group. Conroy T, et al. Among authors: abdelghani mb. Lancet Oncol. 2014 Mar;15(3):305-14. doi: 10.1016/S1470-2045(14)70028-2. Epub 2014 Feb 18. Lancet Oncol. 2014. PMID: 24556041 Clinical Trial.
Single or dual antiplatelet therapy after PCI.
Miyazaki Y, Suwannasom P, Sotomi Y, Abdelghani M, Tummala K, Katagiri Y, Asano T, Tenekecioglu E, Zeng Y, Cavalcante R, Collet C, Onuma Y, Serruys PW. Miyazaki Y, et al. Among authors: abdelghani m. Nat Rev Cardiol. 2017 May;14(5):294-303. doi: 10.1038/nrcardio.2017.12. Epub 2017 Feb 9. Nat Rev Cardiol. 2017. PMID: 28181585 Review.
The year in cardiology 2015: coronary intervention.
Steg PG, Serruys PW, Abdelghani M, Wijns W. Steg PG, et al. Among authors: abdelghani m. Eur Heart J. 2016 Jan 21;37(4):335-43. doi: 10.1093/eurheartj/ehv708. Epub 2016 Jan 3. Eur Heart J. 2016. PMID: 26726048 Review. No abstract available.
Brugada Syndrome: Clinical Features, Risk Stratification, and Management.
Malik BR, Ali Rudwan AM, Abdelghani MS, Mohsen M, Khan SHA, Aljefairi N, Mahmoud E, Asaad N, Hayat SA. Malik BR, et al. Among authors: abdelghani ms. Heart Views. 2020 Apr-Jun;21(2):88-96. doi: 10.4103/HEARTVIEWS.HEARTVIEWS_44_20. Epub 2020 Jun 29. Heart Views. 2020. PMID: 33014301 Free PMC article. Review.
Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
Boige V, Blons H, François E, Ben Abdelghani M, Phelip JM, Le Brun-Ly V, Mineur L, Galais MP, Villing AL, Hautefeuille V, Miglianico L, De La Fouchardière C, Genet D, Levasseur N, Levaché CB, Penel N, Mitry E, Jacquot S, Aparicio T, Brument E, Gourgou S, Castan F, Bouché O. Boige V, et al. Among authors: ben abdelghani m. JAMA Netw Open. 2023 Sep 5;6(9):e2333533. doi: 10.1001/jamanetworkopen.2023.33533. JAMA Netw Open. 2023. PMID: 37721754 Free PMC article. Clinical Trial.
Quantitative aortography assessment of aortic regurgitation.
Modolo R, Chang CC, Onuma Y, Schultz C, Tateishi H, Abdelghani M, Miyazaki Y, Aben JP, Rutten MCM, Pighi M, El Bouziani A, van Mourik M, Lemos PA, Wykrzykowska JJ, Brito FS Jr, Sahyoun C, Piazza N, Eltchaninoff H, Soliman O, Abdel-Wahab M, Van Mieghem NM, de Winter RJ, Serruys PW. Modolo R, et al. Among authors: abdelghani m. EuroIntervention. 2020 Oct 9;16(9):e738-e756. doi: 10.4244/EIJ-D-19-00879. EuroIntervention. 2020. PMID: 31746741 Free article. No abstract available.
From drug eluting stents to bioresorbable scaffolds; to new horizons in PCI.
Tenekecioglu E, Bourantas C, Abdelghani M, Zeng Y, Silva RC, Tateishi H, Sotomi Y, Onuma Y, Yılmaz M, Serruys PW. Tenekecioglu E, et al. Among authors: abdelghani m. Expert Rev Med Devices. 2016;13(3):271-86. doi: 10.1586/17434440.2016.1143356. Epub 2016 Feb 12. Expert Rev Med Devices. 2016. PMID: 26782080 Review.
201 results